Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease

GlobeNewswire June 12, 2020

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia

GlobeNewswire June 8, 2020

Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma

GlobeNewswire May 29, 2020

Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

GlobeNewswire May 19, 2020

Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

GlobeNewswire May 14, 2020

Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 13, 2020

Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

GlobeNewswire May 12, 2020

Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response

GlobeNewswire April 30, 2020

Agios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020

GlobeNewswire April 16, 2020

Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase Deficiency

GlobeNewswire March 30, 2020

Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb

GlobeNewswire March 25, 2020

Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR Activator

GlobeNewswire March 23, 2020

Agios to Present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020

GlobeNewswire February 18, 2020

Agios Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 13, 2020

Agios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020

GlobeNewswire February 11, 2020

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020

GlobeNewswire January 30, 2020

Agios Announces "Agios 2025" Strategic Vision and Highlights 2020 Milestones

GlobeNewswire January 12, 2020

Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

GlobeNewswire December 23, 2019

Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

GlobeNewswire December 16, 2019

Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

GlobeNewswire December 9, 2019